Recursion to Participate in Upcoming Investor Conferences

On September 1, 2022 Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, reported its participation in the following investor conferences (Press release, Recursion Pharmaceuticals, SEP 1, 2022, View Source [SID1234618920]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley Global Healthcare Conference — September 12 through September 14, 2022
Goldman Sachs Global Sustainability Forum — September 29, 2022

bioAffinity Technologies Announces Pricing of IPO

On September 1, 2022 bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, reported that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit (Press release, BioAffinity Technologies, SEP 1, 2022, View Source [SID1234618919]). Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each unit, which has no stand-alone rights and will not be certificated or issued as a stand-alone security, consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share. Each warrant is immediately exercisable and will expire five years from the date of issuance. The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering.

The shares and the tradeable warrants will begin trading on September 1, 2022, on the Nasdaq Capital Market under the ticker symbols "BIAF" and "BIAFW," respectively. The Company intends to use the net proceeds for the commercialization of its diagnostic called CyPath Lung, a non-invasive test for the early detection of lung cancer that has completed a clinical trial showing 92% sensitivity and 87% specificity in detecting lung cancer in individuals at high risk who have lung nodules less than 2 centimeters. Proceeds also will be used for development of tests, additional clinical trials, regulatory filings, and for working capital and general corporate purposes.

WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering.

bioAffinity’s registration statement relating to these securities was declared effective as of August 29, 2022, by the U.S. Securities and Exchange Commission. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained on the SEC’s website, View Source and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at [email protected]

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Fuzionaire to Collaborate with McGill University to Advance Chemistry Platform for Incorporation of Silicon into Pharmaceuticals

On September 1, 2022 Fuzionaire, Inc. reported a collaborative research agreement with McGill University that will leverage the company’s proprietary alkali metal catalyst platform in creating novel heterocyclic, biologically active, silicon-containing scaffolds and new silicon-based drug candidates (Press release, McGill University, SEP 1, 2022, View Source [SID1234618918]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New silicon-containing scaffolds, where a carbon atom is replaced with a silicon atom, would enable a wide array of new silicon-based drug candidates that could have improved efficacy and safety as compared to their carbon-based counterparts.

Silicon is the second-most abundant element in the Earth’s crust. Belonging to the same group in the periodic table as carbon, silicon shares many of its properties, including biocompatibility and low toxicity. Because of slight structural differences, a carbon/silicon switch can modify the biological properties of a drug and potentially enhance its efficacy and safety. Existing drugs that are currently disfavored because of poor biochemical or pharmacokinetic properties could be converted into new silicon forms and used to treat a wide array of diseases.

To date, silicon has not been well-explored in drug development because it is difficult to synthesize silicon-containing structures. Consequently, there are only a small number of silicon-containing compounds under current investigation for pharmaceutical use.

As a platform for the incorporation of silicon into organic molecules, Fuzionaire’s alkali metal catalyst platform could help pave the way for a larger role for silicon in the discovery and design of future generations of pharmaceuticals.

As initially reported in Nature, Fuzionaire’s patented technology enables the incorporation of silicon into organic molecules to create many previously unexplored organosilicon compounds. The synthetic technology is safe and based on an inexpensive potassium catalyst. This is in contrast with many other methods used for incorporating silicon, which often require expensive precious metal catalysts and have other practical limitations.

"The potential upside of using silicon in therapeutics has been recognized for decades, but progress in developing silicon drugs has been impeded, in part, by a lack of general methods to create organosilicon scaffolds," said Jean-Philip Lumb, PhD, Associate Professor of Chemistry at McGill. "With new chemistry, new possibilities are created."

"Silicon-based medicines will be an important part of the future of healthcare, and our goal is for our platform, and the library of scaffolds and pipeline of drug candidates developed with it, to help accelerate this future," said Nick Slavin, co-founder and CEO of Fuzionaire.

Fuzionaire’s collaboration with the Lumb Lab to make new silicon-containing scaffolds and drug candidates will begin with a focus on oncology.

The expertise of McGill and the Lumb Lab in silicon chemistry is longstanding. Since 2020, Fuzionaire affiliate Fuzionaire Diagnostics has been working with McGill in the development of a library of heteroaromatic silicon-fluoride acceptors, or HetSiFAs, as a platform to make diagnostic and theranostic radiopharmaceuticals.

UC San Diego Moores Cancer Center 18th Industry/Academia Next-Generation Precision Oncology Symposium to be held on September 15

On September 1, 2022 Moores Cancer Center at UC San Diego Health, the Office of Industry Relations and Alexandria Real Estate reported that the 18th annual Industry/Academia Next Generation Precision Oncology Symposium will be held Thursday, September 15, at The Alexandria at Torrey Pines (Press release, UC San Diego Moores Cancer Center, SEP 1, 2022, View Source [SID1234618917]). The Symposium serves as a forum for sharing scientific and medical advances in cancer research spanning multiple classes of therapies, with sessions focused on immuno-oncology, solid tumors and hematology/oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of the event, Kristen Hege, MD, Senior Vice President of Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb, will be honored as the 2022 Duane Roth Achievement Award recipient. Dr. Hege is being recognized for her contributions to advancing cancer treatments over her career, including leading the development of Abecma (idecabtagene vicleucel), the first BCMA-directed CAR-T cell therapy approved by the FDA. In addition, Dr. Hege is a Clinical Professor of Medicine at the University of California San Francisco (UCSF), and continues to see patients with blood cancers.

"The Duane Roth Achievement Award is intended to recognize individuals who overcome significant challenges to improve the lives of patients with cancer," said Ida Deichaite, PhD, director of Moores Cancer Center’s Office of Industry Relations and organizer of the symposium. "This year we are proud to recognize Dr. Hege, whose tireless efforts have led to breakthrough therapeutic advances and who continues to engage directly with patients through her role at UCSF."

The Symposium is a forum for leaders in cancer research to present their latest data and translation of research into clinical applications and lifesaving treatment approaches for patients. The Symposium’s emphasis on translational oncology and drug development unites discovery and clinical development researchers, facilitating alliances and partnerships to ultimately accelerate curative therapies that advance global cancer care. Organizers encourage sharing of unpublished data to accelerate research dissemination and discussions that support exchange of knowledge.

Talks presented at the symposium include:

Presentations by researchers from oncology companies, including Bristol Myers Squibb, Dracen Pharmaceuticals, INHIBRx, Mirati Therapeutics, TRACON Therapeutics, and Viracta Therapeutics
Presentations by academic researchers at Moores Cancer Center and UC San Diego across multiple cancer types
About the Duane Roth Endowed Award Lecture

The Duane Roth Endowed Award Lecture is bestowed upon patient-focused leaders in health care whose work has overcome numerous scientific, financial, institutional, political and cultural obstacles to create new paradigms in research and treatment. Named after Duane Roth, an esteemed leader in the biotech industry who was tragically killed following a bicycle accident in 2013, the award is given to those who demonstrate his deep commitment to innovation and the patient. Past recipients include Dennis Carson, MD, UC San Diego; Susan Band Horwitz, PhD, Albert Einstein College of Medicine; Scott Gottlieb, MD, 23rd Commissioner of the Food and Drug Administration; Carl June, MD, University of Pennsylvania School of Medicine; Sandra Horning, MD, head of global product development and chief medical officer, Genentech; Dennis Slamon, MD, PhD, UCLA Jonsson Comprehensive Cancer Center; Brian Druker, MD, Knight Institute at Oregon Health and Science University; and Laura Esserman, MD, UCSF Helen Diller Family Comprehensive Cancer Center. Biographies of past winners and their accomplishments are available online.

MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022

On September 1, 2022 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported that the Company will release its 2022 fiscal year end financial results after the close of the U.S. financial markets on September 8, 2022 (Press release, MEI Pharma, SEP 1, 2022, View Source [SID1234618916]). The Company will host a conference call and live webcast with the investment community to provide a corporate overview and update the same day at 5:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call & Webcast Information

When: September 8, 2022, 5:00 p.m. ET
Dial-in: 1-833-974-2378 (United States) or 1-412-317-5771 (International)
Please ask to join into the MEI Pharma earnings call
Please join the conference call at least 10 minutes early to register. You can access the live webcast under the investor relations section of MEI’s website at: www.meipharma.com. A replay of the conference call will be archived under for at least 30 days after the call.